A GLP-1 Receptor Agonist Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist
Key considerations include the current thyroid status (active hyperthyroidism versus controlled euthyroid state), stability of thyroid function on treatment, presence of complications such as thyroid eye disease or cardiac manifestations, and the patient's overall metabolic health
At 0.25 mg weekly, most patients notice mild changes
Seek immediate medical attention if you experience continuous bleeding lasting more than a week, blood clots in external hemorrhoids, or inability to push a prolapsed hemorrhoid back inside
GLP compliance also helps maintain laboratory personnels safety and the environment
Indeed, many Aetna plans still list Zepbound as an excluded drug in their formularies for 2026